Comparative Pharmacology
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus QVAR 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARMONAIR RESPICLICK versus QVAR 40.
ARMONAIR RESPICLICK vs QVAR 40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Armonair Respiclick is a metered-dose inhaler containing beclomethasone dipropionate, a corticosteroid. It exerts anti-inflammatory effects by binding to glucocorticoid receptors, inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing inflammatory cell migration and cytokine release in the airways.
Beclomethasone dipropionate is a corticosteroid with potent anti-inflammatory activity. It binds to glucocorticoid receptors, leading to modulation of gene expression and inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and inflammation.
Inhaled: 55 mcg to 113 mcg per actuation, 1 to 2 actuations twice daily. Maximum 2 actuations twice daily.
40-160 mcg inhaled twice daily for asthma maintenance; maximum 320 mcg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 26 hours (range 21-36 hours). This supports once-daily dosing for bronchodilation in COPD.
Terminal elimination half-life is approximately 2.9 hours in adults after inhalation, reflecting rapid clearance from plasma.
Renal: approximately 99% of an administered dose is excreted in urine, with 95% as conjugated metabolites and 2% as free arformoterol. Fecal: approximately 1%. Biliary: negligible.
Primarily hepatic metabolism via CYP3A4, with inactive metabolites excreted in feces (approximately 60-70%) and urine (30-40%). Less than 10% excreted unchanged.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid